Our Take
Lilly is using a unilateral deadline to force compliance audits rather than waiting for regulatory clarity, betting hospitals will comply faster than HRSA can act.
Why it matters
The 340B program saves hospitals billions on drugs but lacks real-time audit mechanisms. This move signals pharma is willing to bypass slower government enforcement and set its own terms.
Do this week
Hospital finance and compliance teams: audit your 340B dispensing records against Lilly's data request scope this week so you can respond with confidence by Monday.
Eli Lilly's unilateral compliance push
Eli Lilly has issued a Monday deadline for select hospitals to share data proving they comply with 340B program rules, specifically to demonstrate they are not double-dipping drug discounts. The company says certain hospitals have refused to provide the requested information. Hospitals that received the ultimatum are now urging the federal government, including HRSA (Health Resources and Services Administration), to intervene before the deadline passes.
The 340B program allows eligible hospitals and safety-net providers to purchase select drugs at discounted prices, a mechanism designed to stretch limited budgets. The tension arises because hospitals can also negotiate manufacturer rebates separately, creating an opportunity for abuse if not carefully tracked. Lilly appears unwilling to wait for formal regulatory audits and is instead demanding hospitals prove compliance on its own timeline.
Pharma is moving faster than regulators
HRSA has long struggled to audit 340B abuse in real time. Hospitals report hundreds of billions in annual 340B purchases, but the government lacks granular visibility into which units received discounted drugs and whether they were resold or diverted. Rather than wait for a regulatory framework, Lilly is using its market power and direct relationships with hospitals to create de facto compliance audits.
This sets a precedent. If Lilly's ultimatum succeeds, other manufacturers will likely adopt similar tactics. Hospitals face a choice: comply with individual manufacturer demands (fragmented, resource-intensive) or push back and risk supply disruptions or legal action. The government's ability to maintain control over the 340B program itself is now in question.
What hospital leaders need to do now
Compliance officers and pharmacy directors should immediately pull 340B transaction logs for Lilly drugs and cross-reference them against actual clinical dispensing. Identify any gaps or unexplained discrepancies before the Monday deadline. If you cannot meet the deadline, contact HRSA directly to file a complaint and document the timeline; Lilly's unilateral enforcement may itself violate the statute. Do not assume the government will intervene in time; prepare for both scenarios: submission and escalation.